Design Pharmaceuticals Closes $5 Million Pre-Series A Round To Accelerate Commercialization Of Ultrahigh Throughput Drug Discovery Platform

Company

Location

About

Design Pharmaceuticals harnesses nature’s chemistry of drug-like molecules to develop breakthrough therapeutics. The company’s approach aims to redesign the process of small molecule-based drug discovery and development by using engineering-inspired biotechnologies to access these undiscovered molecules and accelerate the drug discovery process saving time and costs. The platform is based on ultrahigh-throughput technologies that biomine and test drug-like molecules from nature at unprecedented speed and scale on hundreds of GPCR targets simultaneously. Design Pharmaceuticals’ cell-free biosynthesis eliminates the inherent limitations of traditional chemistry or using platforms based on live production strains further accelerating lead compound optimization. The company’s business model aims to build a continuously growing portfolio of joint development and license agreements with pharma partners. For more information, visit www.designpharmaceuticals.com